Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines.
Identifieur interne : 001D47 ( PubMed/Curation ); précédent : 001D46; suivant : 001D48Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines.
Auteurs : Roland Züst [Suisse] ; Luisa Cervantes-Barragán ; Thomas Kuri ; Gjon Blakqori ; Friedemann Weber ; Burkhard Ludewig ; Volker ThielSource :
- PLoS pathogens [ 1553-7374 ] ; 2007.
Descripteurs français
- KwdFr :
- ADN viral, Animaux, Cellules cultivées, Conception de médicament, Données de séquences moléculaires, Délétion de gène, Extinction de l'expression des gènes, Facteurs de virulence (immunologie), Foie (anatomopathologie), Foie (métabolisme), Foie (virologie), Humains, Hépatite virale animale (), Hépatite virale animale (immunologie), Interféron de type I (déficit), Interféron de type I (génétique), Modèles animaux de maladie humaine, Protéines recombinantes (immunologie), Protéines virales non structurales (génétique), Protéines virales non structurales (immunologie), Protéines virales non structurales (métabolisme), Réplication virale, Souris, Souris de lignée C57BL, Souris knockout, Séquence nucléotidique, Vaccins antiviraux (immunologie), Vaccins atténués (immunologie), Virus de l'hépatite murine (immunologie), Virus de l'hépatite murine (pathogénicité).
- MESH :
- anatomopathologie : Foie.
- déficit : Interféron de type I.
- génétique : Interféron de type I, Protéines virales non structurales.
- immunologie : Facteurs de virulence, Hépatite virale animale, Protéines recombinantes, Protéines virales non structurales, Vaccins antiviraux, Vaccins atténués, Virus de l'hépatite murine.
- métabolisme : Foie, Protéines virales non structurales.
- pathogénicité : Virus de l'hépatite murine.
- virologie : Foie.
- ADN viral, Animaux, Cellules cultivées, Conception de médicament, Données de séquences moléculaires, Délétion de gène, Extinction de l'expression des gènes, Humains, Hépatite virale animale, Modèles animaux de maladie humaine, Réplication virale, Souris, Souris de lignée C57BL, Souris knockout, Séquence nucléotidique.
English descriptors
- KwdEn :
- Animals, Base Sequence, Cells, Cultured, DNA, Viral, Disease Models, Animal, Drug Design, Gene Deletion, Gene Silencing, Hepatitis, Viral, Animal (immunology), Hepatitis, Viral, Animal (prevention & control), Humans, Interferon Type I (deficiency), Interferon Type I (genetics), Liver (metabolism), Liver (pathology), Liver (virology), Mice, Mice, Inbred C57BL, Mice, Knockout, Molecular Sequence Data, Murine hepatitis virus (immunology), Murine hepatitis virus (pathogenicity), Recombinant Proteins (immunology), Vaccines, Attenuated (immunology), Viral Nonstructural Proteins (genetics), Viral Nonstructural Proteins (immunology), Viral Nonstructural Proteins (metabolism), Viral Vaccines (immunology), Virulence Factors (immunology), Virus Replication.
- MESH :
- chemical , deficiency : Interferon Type I.
- chemical , genetics : Interferon Type I, Viral Nonstructural Proteins.
- chemical , immunology : Recombinant Proteins, Vaccines, Attenuated, Viral Nonstructural Proteins, Viral Vaccines, Virulence Factors.
- chemical , metabolism : Viral Nonstructural Proteins.
- chemical : DNA, Viral.
- immunology : Hepatitis, Viral, Animal, Murine hepatitis virus.
- metabolism : Liver.
- pathogenicity : Murine hepatitis virus.
- pathology : Liver.
- prevention & control : Hepatitis, Viral, Animal.
- virology : Liver.
- Animals, Base Sequence, Cells, Cultured, Disease Models, Animal, Drug Design, Gene Deletion, Gene Silencing, Humans, Mice, Mice, Inbred C57BL, Mice, Knockout, Molecular Sequence Data, Virus Replication.
Abstract
Attenuated viral vaccines can be generated by targeting essential pathogenicity factors. We report here the rational design of an attenuated recombinant coronavirus vaccine based on a deletion in the coding sequence of the non-structural protein 1 (nsp1). In cell culture, nsp1 of mouse hepatitis virus (MHV), like its SARS-coronavirus homolog, strongly reduced cellular gene expression. The effect of nsp1 on MHV replication in vitro and in vivo was analyzed using a recombinant MHV encoding a deletion in the nsp1-coding sequence. The recombinant MHV nsp1 mutant grew normally in tissue culture, but was severely attenuated in vivo. Replication and spread of the nsp1 mutant virus was restored almost to wild-type levels in type I interferon (IFN) receptor-deficient mice, indicating that nsp1 interferes efficiently with the type I IFN system. Importantly, replication of nsp1 mutant virus in professional antigen-presenting cells such as conventional dendritic cells and macrophages, and induction of type I IFN in plasmacytoid dendritic cells, was not impaired. Furthermore, even low doses of nsp1 mutant MHV elicited potent cytotoxic T cell responses and protected mice against homologous and heterologous virus challenge. Taken together, the presented attenuation strategy provides a paradigm for the development of highly efficient coronavirus vaccines.
DOI: 10.1371/journal.ppat.0030109
PubMed: 17696607
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001D47
Links to Exploration step
pubmed:17696607Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines.</title><author><name sortKey="Zust, Roland" sort="Zust, Roland" uniqKey="Zust R" first="Roland" last="Züst">Roland Züst</name><affiliation wicri:level="1"><nlm:affiliation>Research Department, Kantonal Hospital St. Gallen, St. Gallen, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Research Department, Kantonal Hospital St. Gallen, St. Gallen</wicri:regionArea></affiliation></author><author><name sortKey="Cervantes Barragan, Luisa" sort="Cervantes Barragan, Luisa" uniqKey="Cervantes Barragan L" first="Luisa" last="Cervantes-Barragán">Luisa Cervantes-Barragán</name></author><author><name sortKey="Kuri, Thomas" sort="Kuri, Thomas" uniqKey="Kuri T" first="Thomas" last="Kuri">Thomas Kuri</name></author><author><name sortKey="Blakqori, Gjon" sort="Blakqori, Gjon" uniqKey="Blakqori G" first="Gjon" last="Blakqori">Gjon Blakqori</name></author><author><name sortKey="Weber, Friedemann" sort="Weber, Friedemann" uniqKey="Weber F" first="Friedemann" last="Weber">Friedemann Weber</name></author><author><name sortKey="Ludewig, Burkhard" sort="Ludewig, Burkhard" uniqKey="Ludewig B" first="Burkhard" last="Ludewig">Burkhard Ludewig</name></author><author><name sortKey="Thiel, Volker" sort="Thiel, Volker" uniqKey="Thiel V" first="Volker" last="Thiel">Volker Thiel</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17696607</idno><idno type="pmid">17696607</idno><idno type="doi">10.1371/journal.ppat.0030109</idno><idno type="wicri:Area/PubMed/Corpus">001D47</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D47</idno><idno type="wicri:Area/PubMed/Curation">001D47</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001D47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines.</title><author><name sortKey="Zust, Roland" sort="Zust, Roland" uniqKey="Zust R" first="Roland" last="Züst">Roland Züst</name><affiliation wicri:level="1"><nlm:affiliation>Research Department, Kantonal Hospital St. Gallen, St. Gallen, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Research Department, Kantonal Hospital St. Gallen, St. Gallen</wicri:regionArea></affiliation></author><author><name sortKey="Cervantes Barragan, Luisa" sort="Cervantes Barragan, Luisa" uniqKey="Cervantes Barragan L" first="Luisa" last="Cervantes-Barragán">Luisa Cervantes-Barragán</name></author><author><name sortKey="Kuri, Thomas" sort="Kuri, Thomas" uniqKey="Kuri T" first="Thomas" last="Kuri">Thomas Kuri</name></author><author><name sortKey="Blakqori, Gjon" sort="Blakqori, Gjon" uniqKey="Blakqori G" first="Gjon" last="Blakqori">Gjon Blakqori</name></author><author><name sortKey="Weber, Friedemann" sort="Weber, Friedemann" uniqKey="Weber F" first="Friedemann" last="Weber">Friedemann Weber</name></author><author><name sortKey="Ludewig, Burkhard" sort="Ludewig, Burkhard" uniqKey="Ludewig B" first="Burkhard" last="Ludewig">Burkhard Ludewig</name></author><author><name sortKey="Thiel, Volker" sort="Thiel, Volker" uniqKey="Thiel V" first="Volker" last="Thiel">Volker Thiel</name></author></analytic><series><title level="j">PLoS pathogens</title><idno type="eISSN">1553-7374</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Base Sequence</term><term>Cells, Cultured</term><term>DNA, Viral</term><term>Disease Models, Animal</term><term>Drug Design</term><term>Gene Deletion</term><term>Gene Silencing</term><term>Hepatitis, Viral, Animal (immunology)</term><term>Hepatitis, Viral, Animal (prevention & control)</term><term>Humans</term><term>Interferon Type I (deficiency)</term><term>Interferon Type I (genetics)</term><term>Liver (metabolism)</term><term>Liver (pathology)</term><term>Liver (virology)</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Knockout</term><term>Molecular Sequence Data</term><term>Murine hepatitis virus (immunology)</term><term>Murine hepatitis virus (pathogenicity)</term><term>Recombinant Proteins (immunology)</term><term>Vaccines, Attenuated (immunology)</term><term>Viral Nonstructural Proteins (genetics)</term><term>Viral Nonstructural Proteins (immunology)</term><term>Viral Nonstructural Proteins (metabolism)</term><term>Viral Vaccines (immunology)</term><term>Virulence Factors (immunology)</term><term>Virus Replication</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral</term><term>Animaux</term><term>Cellules cultivées</term><term>Conception de médicament</term><term>Données de séquences moléculaires</term><term>Délétion de gène</term><term>Extinction de l'expression des gènes</term><term>Facteurs de virulence (immunologie)</term><term>Foie (anatomopathologie)</term><term>Foie (métabolisme)</term><term>Foie (virologie)</term><term>Humains</term><term>Hépatite virale animale ()</term><term>Hépatite virale animale (immunologie)</term><term>Interféron de type I (déficit)</term><term>Interféron de type I (génétique)</term><term>Modèles animaux de maladie humaine</term><term>Protéines recombinantes (immunologie)</term><term>Protéines virales non structurales (génétique)</term><term>Protéines virales non structurales (immunologie)</term><term>Protéines virales non structurales (métabolisme)</term><term>Réplication virale</term><term>Souris</term><term>Souris de lignée C57BL</term><term>Souris knockout</term><term>Séquence nucléotidique</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins atténués (immunologie)</term><term>Virus de l'hépatite murine (immunologie)</term><term>Virus de l'hépatite murine (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Interferon Type I</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Interferon Type I</term><term>Viral Nonstructural Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Recombinant Proteins</term><term>Vaccines, Attenuated</term><term>Viral Nonstructural Proteins</term><term>Viral Vaccines</term><term>Virulence Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Viral Nonstructural Proteins</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>DNA, Viral</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Foie</term></keywords><keywords scheme="MESH" qualifier="déficit" xml:lang="fr"><term>Interféron de type I</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Interféron de type I</term><term>Protéines virales non structurales</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Facteurs de virulence</term><term>Hépatite virale animale</term><term>Protéines recombinantes</term><term>Protéines virales non structurales</term><term>Vaccins antiviraux</term><term>Vaccins atténués</term><term>Virus de l'hépatite murine</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Hepatitis, Viral, Animal</term><term>Murine hepatitis virus</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Liver</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Foie</term><term>Protéines virales non structurales</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Murine hepatitis virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus de l'hépatite murine</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Liver</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Hepatitis, Viral, Animal</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Foie</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Liver</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Base Sequence</term><term>Cells, Cultured</term><term>Disease Models, Animal</term><term>Drug Design</term><term>Gene Deletion</term><term>Gene Silencing</term><term>Humans</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Knockout</term><term>Molecular Sequence Data</term><term>Virus Replication</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>ADN viral</term><term>Animaux</term><term>Cellules cultivées</term><term>Conception de médicament</term><term>Données de séquences moléculaires</term><term>Délétion de gène</term><term>Extinction de l'expression des gènes</term><term>Humains</term><term>Hépatite virale animale</term><term>Modèles animaux de maladie humaine</term><term>Réplication virale</term><term>Souris</term><term>Souris de lignée C57BL</term><term>Souris knockout</term><term>Séquence nucléotidique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Attenuated viral vaccines can be generated by targeting essential pathogenicity factors. We report here the rational design of an attenuated recombinant coronavirus vaccine based on a deletion in the coding sequence of the non-structural protein 1 (nsp1). In cell culture, nsp1 of mouse hepatitis virus (MHV), like its SARS-coronavirus homolog, strongly reduced cellular gene expression. The effect of nsp1 on MHV replication in vitro and in vivo was analyzed using a recombinant MHV encoding a deletion in the nsp1-coding sequence. The recombinant MHV nsp1 mutant grew normally in tissue culture, but was severely attenuated in vivo. Replication and spread of the nsp1 mutant virus was restored almost to wild-type levels in type I interferon (IFN) receptor-deficient mice, indicating that nsp1 interferes efficiently with the type I IFN system. Importantly, replication of nsp1 mutant virus in professional antigen-presenting cells such as conventional dendritic cells and macrophages, and induction of type I IFN in plasmacytoid dendritic cells, was not impaired. Furthermore, even low doses of nsp1 mutant MHV elicited potent cytotoxic T cell responses and protected mice against homologous and heterologous virus challenge. Taken together, the presented attenuation strategy provides a paradigm for the development of highly efficient coronavirus vaccines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17696607</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>8</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>PLoS pathogens</Title><ISOAbbreviation>PLoS Pathog.</ISOAbbreviation></Journal><ArticleTitle>Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines.</ArticleTitle><Pagination><MedlinePgn>e109</MedlinePgn></Pagination><Abstract><AbstractText>Attenuated viral vaccines can be generated by targeting essential pathogenicity factors. We report here the rational design of an attenuated recombinant coronavirus vaccine based on a deletion in the coding sequence of the non-structural protein 1 (nsp1). In cell culture, nsp1 of mouse hepatitis virus (MHV), like its SARS-coronavirus homolog, strongly reduced cellular gene expression. The effect of nsp1 on MHV replication in vitro and in vivo was analyzed using a recombinant MHV encoding a deletion in the nsp1-coding sequence. The recombinant MHV nsp1 mutant grew normally in tissue culture, but was severely attenuated in vivo. Replication and spread of the nsp1 mutant virus was restored almost to wild-type levels in type I interferon (IFN) receptor-deficient mice, indicating that nsp1 interferes efficiently with the type I IFN system. Importantly, replication of nsp1 mutant virus in professional antigen-presenting cells such as conventional dendritic cells and macrophages, and induction of type I IFN in plasmacytoid dendritic cells, was not impaired. Furthermore, even low doses of nsp1 mutant MHV elicited potent cytotoxic T cell responses and protected mice against homologous and heterologous virus challenge. Taken together, the presented attenuation strategy provides a paradigm for the development of highly efficient coronavirus vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Züst</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Research Department, Kantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervantes-Barragán</LastName><ForeName>Luisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kuri</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Blakqori</LastName><ForeName>Gjon</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Friedemann</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ludewig</LastName><ForeName>Burkhard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Thiel</LastName><ForeName>Volker</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>AF304460</AccessionNumber><AccessionNumber>AY291315</AccessionNumber><AccessionNumber>AY700211</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R21 AI062246</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5 R21 AI062246</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Pathog</MedlineTA><NlmUniqueID>101238921</NlmUniqueID><ISSNLinking>1553-7366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C505227">NSP1 protein, murine hepatitis virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037521">Virulence Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020868" MajorTopicYN="N">Gene Silencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006524" MajorTopicYN="N">Hepatitis, Viral, Animal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006517" MajorTopicYN="N">Murine hepatitis virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D037521" MajorTopicYN="N">Virulence Factors</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>02</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17696607</ArticleId><ArticleId IdType="pii">07-PLPA-RA-0063</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.0030109</ArticleId><ArticleId IdType="pmc">PMC1941747</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Virol. 2003 Sep;77(18):9790-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12941887</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Apr;81(7):3151-61</Citation><ArticleIdList><ArticleId IdType="pubmed">17202208</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Immunol. 2005 Jan;26(1):13-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15629404</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2005 Oct 1;106(7):2366-74</Citation><ArticleIdList><ArticleId IdType="pubmed">15860669</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Mar;81(6):2554-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17182678</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunology. 2000 Feb;99(2):163-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10692032</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Oct;79(20):12721-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16188975</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Nov;80(22):11009-18</Citation><ArticleIdList><ArticleId IdType="pubmed">16943300</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2002 Apr 25;296(1):177-89</Citation><ArticleIdList><ArticleId IdType="pubmed">12036329</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2005 Dec;5(12):917-27</Citation><ArticleIdList><ArticleId IdType="pubmed">16322745</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Nov;79(21):13399-411</Citation><ArticleIdList><ArticleId IdType="pubmed">16227261</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Jan;79(2):1036-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15613332</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2004 Jun;85(Pt 6):1717-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15166457</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12885-90</Citation><ArticleIdList><ArticleId IdType="pubmed">16912115</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2003 Mar 30;308(1):13-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12706086</ArticleId></ArticleIdList></Reference><Reference><Citation>FEMS Microbiol Rev. 2006 Sep;30(5):760-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16911043</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2006 Nov 10;314(5801):997-1001</Citation><ArticleIdList><ArticleId IdType="pubmed">17038589</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Apr;78(8):3863-71</Citation><ArticleIdList><ArticleId IdType="pubmed">15047802</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1998 Apr 10;273(15):8699-704</Citation><ArticleIdList><ArticleId IdType="pubmed">9535846</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2005 Apr;11(4 Suppl):S54-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15812491</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2002 Feb;76(3):1422-34</Citation><ArticleIdList><ArticleId IdType="pubmed">11773416</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Sep 30;340(2):209-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16051301</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(5):3097-106</Citation><ArticleIdList><ArticleId IdType="pubmed">15709029</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Top Microbiol Immunol. 2005;287:161-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15609512</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Mar;80(5):2506-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16474157</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2007 Feb 1;109(3):1131-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16985170</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1997 Jun;45(6):706-11</Citation><ArticleIdList><ArticleId IdType="pubmed">9180664</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Jan;81(2):548-57</Citation><ArticleIdList><ArticleId IdType="pubmed">17108024</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2005 Apr;11(4 Suppl):S5-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15812490</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2002 Nov;76(22):11518-29</Citation><ArticleIdList><ArticleId IdType="pubmed">12388713</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1994 Jun 24;264(5167):1918-21</Citation><ArticleIdList><ArticleId IdType="pubmed">8009221</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 2006;581:203-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17037531</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2006 Feb 4;367(9508):425-35</Citation><ArticleIdList><ArticleId IdType="pubmed">16458769</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2001 Jun;82(Pt 6):1273-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11369870</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(6):3391-400</Citation><ArticleIdList><ArticleId IdType="pubmed">15731233</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation><ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 1991 Jun;33(1-2):191-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1939506</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2006 Jan 5;344(1):119-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16364743</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2007 Jan;3(1):e5</Citation><ArticleIdList><ArticleId IdType="pubmed">17222058</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Infect Dis Rep. 2004 Apr;6(2):96-104</Citation><ArticleIdList><ArticleId IdType="pubmed">15023271</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1998 Feb 16;17(4):1087-95</Citation><ArticleIdList><ArticleId IdType="pubmed">9463386</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Jun;79(12):7819-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15919935</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Jan;81(2):813-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17079315</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbiol Mol Biol Rev. 2005 Dec;69(4):635-64</Citation><ArticleIdList><ArticleId IdType="pubmed">16339739</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2006 Jan 5;344(1):9-16</Citation><ArticleIdList><ArticleId IdType="pubmed">16364730</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8275-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15919828</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2006 Feb 24;124(4):849-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16497593</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 May;78(10):5486-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15113927</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4309-14</Citation><ArticleIdList><ArticleId IdType="pubmed">10725408</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Top Microbiol Immunol. 2005;287:57-94</Citation><ArticleIdList><ArticleId IdType="pubmed">15609509</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Feb;81(3):1162-73</Citation><ArticleIdList><ArticleId IdType="pubmed">17108019</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001D47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:17696607
|texte= Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:17696607" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |